WRWilliam F van Rodijnen

William F van Rodijnen

*This is an algorithmically generated author record based on publicly available information.

William F van Rodijnen has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Geert-Jan Tangelder

    Laboratory for Physiology, Vrije Universitet

    1 shared publication
  • Marco E van Teijlingen

    Laboratory for Physiology, Vrije Universitet

    1 shared publication
  • Piet M ter Wee

    Department of Nephrology, Institute for Cardiovascular Research (ICaR-VU), Vrije Universiteit, Amsterdam, The Netherlands

    1 shared publication
  • Ton A van Lambalgen

    Laboratory for Physiology, Vrije Universitet

    1 shared publication

Latest Publications

  • Open Access

    Comparison of the AT1-receptor blockers candesartan, irbesartan and losartan for inhibiting renal microvascular constriction

    by William F van Rodijnen, Ton A van Lambalgen, Marco E van Teijlingen, Geert-Jan Tangelder, Piet M ter Wee

    Angiotensin II (Ang II) type 1 (AT1) receptor blockers differ in their affinity for the AT1-receptor, suggesting a dissimilar potency for inhibiting Ang II-induced vascular constriction. In the present study, we compared the effects of candesartan, irbesartan and losartan on the renal microvascular constriction to locally-formed Ang II, using isolated, perfused hydronephrotic rat kidneys. Addition of 1 nmol/L angiotensin I (Ang I, the precursor of Ang II) significantly reduced the diameters of interlobular arteries (ILAs; -47.6±2.6%), afferent arterioles (AAs; -43.6±2.3%) and efferent arterioles (EAs; -31.6±2.4%). Candesartan and irbesartan were more potent in antagonising the constriction to Ang I than losartan. By contrast, candesartan and irbesartan differed only slightly in potency. After a washing period of 60 minutes with drug-free medium, a second application of Ang I failed to induce vasoconstriction only in candesartan-treated kidneys. Pretreatment of hydronephrotic kidneys with candesartan, to further explore its antagonistic properties, shifted the dose-response curves of Ang II approximately 2 log units to the right without reducing the maximal Ang II-induced constriction of ILAs, AAs or EAs. Additionally, dose-response curves of Ang II were similar after short (10 minutes) and prolonged (60 minutes) preincubation with candesartan. Our findings indicate that candesartan and irbesartan are more potent inhibitors of renal microvascular constriction to locally-formed Ang II than losartan. The inhibitory effect of candesartan is more prolonged, suggesting a slow dissociation from the AT1-receptor. Additionally, candesartan was found to block the Ang II-induced constriction of renal microvessels in a surmountable manner.